Communications Biology

OCT 23, 2026 · JOURNAL ARTICLE

Dysregulation of the Hippo pathway enhances PD-L2 transcription to promote immune evasion in head and neck squamous cell carcinoma

Communications Biology

Abstract The Hippo pathway and its downstream effectors, YAP/TAZ, exhibit aberrant regulation in head and neck squamous cell carcinoma, facilitating cancer cell growth. However, th

OCT 16, 2026 · JOURNAL ARTICLE

BUB signaling in cancer and molecular insights into targeted therapies

Communications Biology

Abstract The Spindle Assembly Checkpoint (SAC) is vital for proper chromosome segregation during cell division and for maintaining genomic integrity; its disruption can cause aneup

OCT 7, 2026 · JOURNAL ARTICLE

ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner

Communications Biology

Abstract ESR1 mutations are a driver of endocrine therapy resistance in breast cancer, however their impact on protein signaling pathways and clinical outcomes remains poorly under

SEP 21, 2026 · JOURNAL ARTICLE

Harnessing microfluidics for microbiology: from bacteria-host interactions to emerging cancer therapies

Communications Biology

Microfluidics has emerged as a powerful technology for precisely controlling mechanical and chemical environments across a wide range of biological systems, from single cells to co

SEP 19, 2026 · JOURNAL ARTICLE

pH-responsive hyaluronic acid nanocarrier activates cGAS/STING-mediated immunotherapy in colorectal cancer

Communications Biology

Colorectal cancer ranks as the third most common cancer and the second leading cause of cancer-related mortality worldwide. Kaempferol is a natural flavonoid with reported anti-col

SEP 9, 2026 · JOURNAL ARTICLE

TRIM21-dependent ubiquitination of MCCase induced by hsa_circ_0009061 drives H3K36 crotonylation to suppress epithelial ovarian cancer progression through regulating glycolysis

Communications Biology

Mechanistic cell and animal study proposing a circRNA-protein-histone pathway in ovarian cancer; no clinical trial data, human efficacy endpoints, or comparison to standard therapy reported.

AUG 11, 2026 · JOURNAL ARTICLE

Multimodal profiling of HER2/neu-specific TCR-T cells reveals clonotype-dependent activation programs underlying differential cytotoxic efficacy

Communications Biology

Single-centre mechanistic study of three TCR constructs using multimodal profiling with in vivo tumour modelling; identifies functional hierarchy but lacks comparative efficacy statistics, power calculation, or clinical translation.